Difficult. Impossible. Agonizing. Worse than voting in the national election. | Difficult. Impossible. Agonizing. Worse than ...

Abbott has received an FDA clearance for the latest version of its sensor-laden catheter used to map out the electrical ...

Capricor Therapeutics is taking a victory lap for their phase 2 Duchenne muscular dystrophy (DMD) trial. | Capricor ...

In order to focus its resources on the phase 1 program, dubbed TIDAL-01, the company has today announced a reduction in staff ...

In a year that has seen an approval and a raft of readouts for metabolic dysfunction-associated steatohepatitis (MASH), ...

Bruker has formed a new, single division out of the various spatial biology assets it has acquired over the years. | Bruker ...

Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 Therapeutics this morning in becoming the latest ...

Gritstone bio may have left no stone unturned when it came to searching for a financial rescue, but the vaccine biotech has ...

Ono Pharmaceutical has bought a seat in a quiet corner of the congested antibody-drug conjugate (ADC) space, agreeing | Ono ...

The digital diabetes developer Glooko has collected $100 million and a new CEO to help boost the trajectory of its data ...

Immatics has vaulted into phase 3 on the strength of early-stage data. The biotech is gearing up to start a pivotal trial of ...

Alaunos Therapeutics is axing an agreement with Precigen, giving up licensing rights to a personalized T-cell platform. | ...